UP 1009
Alternative Names: UP-1009Latest Information Update: 12 Sep 2024
At a glance
- Originator UPPTHERA
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell cycle protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 22 Jul 2024 UP 1009 is available for licensing as of 22 Jul 2024. https://www.uppthera.com/about-us/partnerships/
- 22 Jul 2024 Early research in Cancer in South Korea (unspecified route) (Uppthera pipeline, July 2024)